|
gemtuzumab ozogamicin
gemtuzumab ozogamicin
information and resources from the National Cancer Institute
NCI Thesaurus | gemtuzumab ozogamicin
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. NCI Thesaurus | gemtuzumab ozogamicin
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis.
Mylotarg
Accel. Approv. (clinical benefit not established) Treatment of CD33 positive acute myeloid leukemia in patients in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy.
Wyeth Ayerst May 17 2000
|
|
|
|
|
|
National Study Improves Outcome For Pediatric Acute Myeloid ... Dec 14, 2005
Science Daily (press release) Patients found to have no response to ADE during induction therapy were subsequently treated with low-dose ADE plus gemtuzumab ozogamicin (GO), while all ...
gemtuzumab ozogamicin
-->
|
